Rockefeller Capital Management
LCTX icon

Rockefeller Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Rockefeller Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.07K Hold
5,309
– – ﹤0.01% 4378
2026
Q2 		$6.96K Hold
5,309
– – ﹤0.01% 4147
2026
Q1 		$8.39K Sell
5,309
-198
-4% -$334 ﹤0.01% 4069
2025
Q4 		$9.2K Buy
5,507
+29
+0.5% +$50 ﹤0.01% 3841
2025
Q3 		$9.26K Buy
+5,478
New +$6.48K ﹤0.01% 3678
2023
Q1 		– Sell
-280
Closed – – 3043
2022
Q4 		$0 Hold
280
– – ﹤0.01% 4054
2022
Q3 		$0 Hold
280
– – ﹤0.01% 4159
2022
Q2 		$0 Buy
+280
New +$369 ﹤0.01% 4265
2020
Q1 		– Sell
-1,100
Closed -$1K – 2425
2019
Q4 		$1K Buy
+1,100
New +$916 ﹤0.01% 1983

Other funds holding LCTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Defender Capital
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rockefeller Capital Management's LCTX Position: Q3 2026 in Review

Rockefeller Capital Management held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 5,309 shares worth $5.07K. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

Rockefeller Capital Management first reported a position in LCTX in Q4 2019 and has held it in 9 quarters since. The position peaked at $9.26K in Q3 2025. 109 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Rockefeller Capital Management held 5,309 shares of Lineage Cell Therapeutics worth $5.07K as of Q3 2026.
  • Rockefeller Capital Management left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4378 holding.
  • Rockefeller Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2019 and has held it in 9 quarters since.
  • Rockefeller Capital Management's Lineage Cell Therapeutics position peaked at $9.26K in Q3 2025.
  • 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.